Inovio Pharmaceuticals and GeneOne Life Science have dosed the first patient in the multi-center, phase I clinical trial of the companies’ Zika vaccine.
The first of its kind trial has successfully identified several compounds to pursue and has given rise to more than a dozen drug development projects.
Cambrex has said it will invest around $20m in its Pharma 4 API facility before the end of the year in an effort to get ahead of the capacity utilisation curve.
As part of a recent survey, 62% of respondents said they are more likely to engage a clinical research organization (CRO) partner for clinical research than they were five years ago.
While the industry has made progress in advancing diversity in clinical trials, greater expectations may be forthcoming.
Content Provided by World Courier
In globalising the pharmaceutical industry oversight and control has increasingly become a challenge in managing product quality, consumer safety and organisational risk.